Bartlett & Co’s Exelixis EXEL Stock Holding History

Bartlett & Co’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12	Closed	–	–	974
2021 Q2	$0	Hold	12	–	–	﹤0.01%	1037
2021 Q1	$0	Hold	12	–	–	﹤0.01%	1090
2020 Q4	$0	Buy	+12	New	+$251	﹤0.01%	1164

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bartlett & Co's EXEL Position: Q3 2021 in Review

Bartlett & Co sold out of Exelixis (EXEL) in Q3 2021, closing a stake of 12 shares.

Bartlett & Co first reported a position in EXEL in Q4 2020 and held it in 3 quarters. The position peaked at $0 in Q2 2021. 339 funds tracked by Wall St. Rank hold EXEL as of Q3 2021.

Bartlett & Co reported no remaining Exelixis position as of Q3 2021 after selling out during the quarter.
Bartlett & Co sold 12 Exelixis shares in Q3 2021.
Bartlett & Co first reported a position in Exelixis in Q4 2020 and held it in 3 quarters.
Bartlett & Co's Exelixis position peaked at $0 in Q2 2021.
339 funds tracked by Wall St. Rank held Exelixis as of Q3 2021.

Based on Bartlett & Co's 13F filing for Q3 2021, filed 15 Oct 2021.